EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrel

Alison Edelman, Jeffrey T Jensen, Jill Brown, Michael Thomas, David F Archer, Courtney A Schreiber, Stephanie Teal, Carolyn Westhoff, Clint Dart, Diana L Blithe

Contraception · 2024

DOI: 10.1016/j.contraception.2024.110474 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Contraception, 2024. Verfasst von Alison Edelman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of OB/GYN, Oregon Health & Science University, Portland, OR, United States. Electronic address: edelmana@ohsu.edu. Hauptthemen laut MEDLINE: Levonorgestrel, Norpregnadienes, Contraception, Postcoital. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, National Institute of Child Health and Human Development, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To compare the efficacy of emergency contraception (EC) regimens used within 72 hours of unprotected intercourse in individuals weighing ≥80 kg. STUDY DESIGN: We enrolled reproductive-aged healthy women in a multicenter, single-blind, randomized study of levonorgestrel 1.5 mg (LNG1X) and 3.0 mg (LNG2X) and ulipristal acetate 30 mg (UPA) (enrollment goal 1200). Key eligibility requirements included regular cycles, weight >/= 80kg, unprotected intercourse within 72 hours, no recent use of hormonal contraception, a negative urine pregnancy test (UPT), and willingness to abstain from intercourse until next menses. To assess our primary outcome of incidence of pregnancy, participants completed home UPTs; if no menses by 2-weeks post-treatment, or a positive UPT, they returned for an in-person visit with quantitative serum human chorionic gonadotropin and ultrasound. RESULTS: We enrolled and randomized 532; 44 were not dosed or not evaluable for primary end point, leaving an analyzable sample of 488 (173 LNG1X, 158 LNG2X, 157 UPA) with similar demographics between groups (mean age 29.6 years [5.74], body mass index 37.09 kg/m2 [6.95]). Five pregnancies occurred (LNG1X n = 1, LNG2X n = 1, UPA n = 3); none occurred during the highest at-risk window (day of ovulation and the 3 days prior). We closed the study before achieving our enrollment goal because the low pregnancy rate in all groups established futility based on an interim blinded analysis. CONCLUSIONS: Although slow enrollment limited our study power, we found no differences in pregnancy rates between EC regimens among women weighing 80 kg or more. Our results are not able to refute or support differences between the treatment arms. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clincialtrials.gov Clinical trials#: NCT03537768. IMPLICATIONS: Women weighing 80 kg or more experienced no differences in pregnancy rates between oral EC regimens but due to several significant study limitations including sample size and the lack of a study population at high risk of pregnancy, our results are not able to determine if differences in treatment effectiveness exist.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevonorgestrelNorpregnadienesContraception, PostcoitalHumansFemaleAdultPregnancySingle-Blind MethodYoung AdultBody WeightAdolescentPregnancy Rate

Stichwörter der Autor:innen

BMIEmergency contraceptionLevonorgestrelObesityUlipristal acetate

Substanzen

LevonorgestrelNorpregnadienesulipristal acetate

Autor:innen und Institutionen

  • Department of OB/GYN, Oregon Health & Science University, Portland, OR, United States. Electronic address: edelmana@ohsu.edu.
  • Department of OB/GYN, Oregon Health & Science University, Portland, OR, United States.
  • Department of OB/GYN, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
  • Department of OB/GYN, University of Cincinnati, Cincinnati, OH, United States.
  • Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA, United States.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

Förderung

  • NICHD NIH HHS
  • National Institute of Child Health and Human Development
  • National Institutes of Health
  • NICHD

Zitieren

APA

Edelman, A., Jensen, J. T., Brown, J., Thomas, M., Archer, D. F., Schreiber, C. A., Teal, S., Westhoff, C., Dart, C., & Blithe, D. L. (2024). Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrel. Contraception. https://doi.org/10.1016/j.contraception.2024.110474

Vancouver

Edelman A, Jensen JT, Brown J, Thomas M, Archer DF, Schreiber CA, et al. Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrel. Contraception. 2024. doi:10.1016/j.contraception.2024.110474

BibTeX
@article{Edelman2024,
  author = {Edelman, Alison and Jensen, Jeffrey T and Brown, Jill and Thomas, Michael and Archer, David F and Schreiber, Courtney A and Teal, Stephanie and Westhoff, Carolyn and Dart, Clint and Blithe, Diana L},
  title = {Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrel},
  journal = {Contraception},
  year = {2024},
  doi = {10.1016/j.contraception.2024.110474}
}
Kostenlos starten →